<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>29030</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">29030</infon><infon key="article-id_pmid">11056739</infon><infon key="article-id_publisher-id">cc-3-6-145</infon><infon key="fpage">145</infon><infon key="issue">6</infon><infon key="journal-title">Critical Care</infon><infon key="kwd">medications prophylaxis stress ulcers survey</infon><infon key="lpage">149</infon><infon key="name_0">surname:Erstad;given-names:Brian L</infon><infon key="name_1">surname:Barletta;given-names:Jeffrey F</infon><infon key="name_2">surname:Jacobi;given-names:Judith</infon><infon key="name_3">surname:Killian;given-names:Aaron D</infon><infon key="name_4">surname:Kramer;given-names:Katherine M</infon><infon key="name_5">surname:Martin;given-names:Steven J</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">1999</infon><offset>0</offset><text>Survey of stress ulcer prophylaxis</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>35</offset><text>Background:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>47</offset><text>No surveys of stress ulcer prophylaxis prescribing in the USA have been conducted since 1995. Since that time, the most comprehensive meta-analysis and largest randomized study to date concerning stress ulcer prophylaxis have been published.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>289</offset><text>Results:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>298</offset><text>Three hundred sixty-eight surveys were sent to all members of the Section of Pharmacy and Pharmacology of the Society of Critical Care Medicine. One hundred fifty-three (42%) surveys were returned. Representatives from 86% of institutions stated that medications for stress ulcer prophylaxis are used in a majority (&gt;90%) of patients admitted to the intensive care unit (ICU). Twenty-two per cent of institutions have recommendations for both ICU and non-ICU settings. Fifty-eight per cent of institutions stated that there was one preferred medication for stress ulcer prophylaxis, and in 77% of these histamine-2-antagonists were the most popular.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>948</offset><text>Conclusions:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>961</offset><text>There are wide variations in prescribing practices for stress ulcer prophylaxis. Institutions should consult published literature and use pre-existing guidelines as templates for developing their own guidelines.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1173</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1186</offset><text>Stress-induced gastroduodenal erosions are a frequent occurrence in 		  critically ill patients, but it is the incidence of clinically important 		  complications resulting from these erosions that is important in deciding which 		  patients should receive prophylaxis. Clinically important complications include 		  bleeding that requires transfusion, bleeding associated with hemodynamic 		  instability, and gastrointestinal perforations. Failure to document these 		  complications in published studies limits the conclusions that can be drawn 		  from much of the available literature. There have been inconsistent results in 		  those studies that did record clinically important bleeding, depending on 		  severity of illness or injury, and concomitant or underlying disease 		  states.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1980</offset><text>Because the results of clinical investigations have led to different 		  recommendations concerning stress ulcer prophylaxis, Cook et al performed a meta-analysis of randomized trials to resolve the 		  controversies associated with previous research in this area. They concluded 		  that there was no clear agent of choice for prophylaxis based on efficacy 		  considerations (ie ability to prevent clinically important bleeding), but 		  sucralfate might have advantages in terms of adverse effects because it was 		  associated with a lower incidence of pneumonia compared with histamine-blocking 		  medications. Within 2 years of the publication of this meta-analysis, Cook 		  et al reported their findings from the 		  largest randomized study conducted to date concerning stress ulcer prophylaxis. 		  In that study, intravenous ranitidine 50 mg/8 h (with dose decreased for renal 		  dysfunction) was associated with a lower incidence of clinically important 		  bleeding compared with sucralfate 1 g/6 h (relative risk 0.44, 95% confidence 		  interval 0.21⌓0.92, P = 0.02). There were no significant differences 		  between the medications with respect to pneumonia or mortality.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3173</offset><text>Given the recent publication of these important results, the present 		  survey was conducted by members of the Research Committee of the Section of 		  Pharmacy and Pharmacology of the Society of Critical Care Medicine. The survey 		  was mailed to Section members who are well versed in medications used in the 		  critical care area. The purpose of the survey was to determine current 		  prescribing practices in light of recent publications concerning stress ulcer 		  prophylaxis. The survey was also intended to assess institutional evaluations 		  of stress ulcer prophylaxis. It is hoped that the results of this survey will 		  provide clinicians with information as to how their prescribing and evaluation 		  practices compare with those of practitioners in other institutions. 		  Additionally, the survey might uncover institutional practices that are 		  inconsistent with the available literature and that deserve further 		  consideration.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4130</offset><text>Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4152</offset><text>A survey was developed that contained questions regarding 		  institutional prescribing and evaluation of stress ulcer prophylaxis. There 		  were 11 questions on the survey, although several of the questions asked for 		  additional information, depending on the initial response. The length of the 		  survey was a compromise between asking enough questions to determine patterns 		  of medication use and evaluation without discouraging completion of the survey 		  by unnecessary length. The majority of questions were in a 'yes/no' 		  format with further information required on the basis of the initial response. 		  For example, one question was 'Does your institution have written 		  guidelines for stress ulcer prophylaxis?' If the answer to this question 		  was 'yes', then the responder was asked an additional series of 		  questions concerning the details of these guidelines.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5045</offset><text>Several of the questions requested information that required answers 		  as a percentage value. For example, 'What percentage of patients 		  discharged from the intensive care unit to non-intensive care unit settings 		  remain on stress ulcer prophylaxis?' For this type of question, the 		  responder was requested to select from a range of percentages, such as 0⌓25%, 		  26⌓50%, 51⌓75%, or 76⌓100%. Most of the remaining questions allowed answers in 		  either a check box or free text format.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5552</offset><text>A series of steps were taken in order to improve the validity and 		  reliability of the instrument. After the initial survey construction at one 		  site, the instrument was distributed to selected members of the Section of 		  Pharmacy and Pharmacology of the Society of Critical Care Medicine for 		  pretesting of the instrument. Additionally, a physician who practices in the 		  critical care setting (but is not a member of the Section) was asked to review 		  the instrument. Changes were made to the document on the basis of this 		  input.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6102</offset><text>The survey was sent to all members of the Section of Pharmacy and 		  Pharmacology of the Society of Critical Care Medicine in the fall of 1998. A 		  stamped, self-addressed envelope was included in the mailing for returning the 		  completed surveys. Descriptive statistics were used to analyze and report the 		  data, because the answers were not amenable to inferential testing. Data were 		  recorded and analyzed using Microsoft Excel version 4.0 (Microsoft 		  Corporation).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>6585</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6593</offset><text>A total of 368 surveys were distributed and 153 were returned, 		  yielding a response rate of 42%. Of the hospitals surveyed 62% had more than 		  400 beds, and 32% had between 200 and 399 beds. Sixty-one per cent of 		  institutions had more than 40 intensive care unit (ICU) beds and 29% had 		  between 20 and 39 beds. It is difficult to comment on the focus of the ICUs (ie 		  surgical, medical, mixed or special) because of many respondents checking more 		  than one item. Sixty-one per cent were classified as level I trauma centers. Of 		  institutions 86% stated that medications for stress ulcer prophylaxis are used 		  in a vast majority (&gt; 90%) of patients admitted to the ICU. Twenty-two per 		  cent have recommendations for both ICU and non-ICU settings. These differences 		  are provided in Table 1.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7413</offset><text>The majority of questions on the survey pertained to stress ulcer 		  prophylaxis from an overall institutional standpoint. There were a few 		  questions, however, that attempted to define specialized populations at the 		  institutions that might be at particular risk for stress ulceration and related 		  complications. With the exception of multiple trauma, these injuries can be 		  considered as 'single-system' problems. The number of institutions 		  that routinely institute stress ulcer prophylaxis in these specialized 		  populations is listed in Table 2.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7982</offset><text>Twenty-seven per cent of institutions have written guidelines for 		  stress ulcer prophylaxis, with approximately half of those stating that their 		  guidelines have been reviewed or updated within the past 2 years. Of responders 		  40% are either considering or developing guidelines for their respective 		  institutions.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8309</offset><text>Fifty-eight per cent of institutions stated that there is one 		  preferred medication for stress ulcer prophylaxis. For those institutions, 		  histamine-2-antagonists were the most popular in 77%. Sucralfate was the agent 		  of choice in 20%, whereas omeprazole was preferred in 3%. Antacids were not the 		  agents of choice in any institution. A breakdown of the route of administration 		  for each agent is listed in Table 3.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8742</offset><text>Ten per cent of institutions evaluated the incidence of clinically 		  important bleeding, which was defined as the need for transfusion or 		  hemodynamic changes that are associated with bleeding. It is unclear whether 		  these institutions limited their evaluation to patients receiving stress ulcer 		  prophylaxis due to the limited number of respondents who answered that question 		  (n =13). Twenty-three per cent routinely used gastric pH measurements 		  (ie pH paper, pH sensor, gastric tonometry) for monitoring pH-altering agents 		  when such measurements were feasible.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>9328</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>9339</offset><text>As indicated by the results of this survey, stress ulcer prophylaxis 		  is used in the majority (86%) of critically ill patients. Although it is 		  difficult (if not impossible) for any survey to elucidate the reasons why 		  physicians prescribe the way they do, it is possible to hypothesize from the 		  results of our questionnaire. For most clinicians, it appears that the presumed 		  benefits of prophylaxis outweigh its associated risks and costs. Consistent 		  with a small percentage of individuals returning the surveys, however, there 		  are clinicians who believe the value of prophylaxis is overstated and question 		  its widespread use. This opinion is based on the perception that the incidence 		  of bleeding is rare, and when it does occur it is readily amenable to 		  endoscopic or medical therapies.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10166</offset><text>The number of patients receiving stress ulcer prophylaxis in non-ICU 		  settings is concerning. Of institutions surveyed 22% stated that stress ulcer 		  prophylaxis is given to patients in non-ICU settings more than 50% of the time. 		  Also, patients discharged from ICU to non-ICU settings remain on stress ulcer 		  prophylaxis more than 50% of the time in 33% of institutions. Given the lack of 		  published literature in non-ICU settings, along with the low risk of clinically 		  important bleeding, many experts believe that routine prophylaxis is not 		  warranted. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10744</offset><text>The incidence of stress-induced bleeding has varied considerably, 		  depending on the definition of bleeding and the population under study. Both 		  microscopic and macroscopic (ie overt) bleeding are relatively common findings 		  in published studies, but there is no well documented relationship between such 		  bleeding and the incidence of clinically important bleeding complications (eg 		  hemodynamic instability, perforation, need for transfusion). Unfortunately, 		  the actual incidence of clinically important bleeding associated with many 		  published investigations is not available, particularly in those published 		  before 1990. In randomized trials conducted since 1990 that enrolled at least 		  100 general medical/surgical ICU patients, the incidence of clinically 		  important bleeding associated with no prophylaxis has ranged from 3.5 to 22.9%. In this survey, only 10% of 		  the surveyed institutions evaluated the incidence of clinically important 		  bleeding.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11739</offset><text>Certain types of defined or single-system injuries appear to be 		  associated with a higher incidence of bleeding, on the basis of retrospective 		  data. In the present study, the great majority of patients with head, spinal 		  cord, thermal, or hepatic injuries were routinely given prophylaxis. Using 		  thermal injury as an example, however, only one randomized trial has been 		  conducted, the results of which were published in 1976. In that trial, 29.2% of patients not receiving prophylaxis 		  had clinically important bleeding, compared with 4.2% of patients receiving 		  antacid prophylaxis (P &lt; 0.02). Using adult patients with head 		  injuries (Glasgow Coma Scores ≤ 10) as another example, one trial 		  published in 1993 (n = 167) found no 		  instances of clinically important bleeding with either saline placebo or 		  ranitidine, whereas another trial published in 1995 (n = 34) found that 27.8% of patients receiving no prophylaxis had 		  clinically important bleeding compared with none of the patients in the 		  ranitidine group (P ≤ 0.05).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12813</offset><text>Some of the variation in bleeding rates in published studies may be 		  attributable to the definition used for delineating patients at risk for 		  stress-induced complications. Two risk factors have been found to be predictive 		  of clinically important bleeding using multivariate analytic techniques in a 		  large sample of mixed medical/surgical patients. 		  These risk factors are respiratory failure requiring mechanical ventilation, 		  and coagulopathy. It is unknown whether these findings are applicable to more 		  homogeneous, specialized populations (eg patients with burns or trauma, or 		  patients undergoing central nervous system surgery) because of lack of study 		  inclusion or insufficient enrolment numbers.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>13548</offset><text>Once the decision is made to use prophylaxis, there are several 		  medications available. In the present investigation, 77% of the institutions 		  surveyed used histamine-2-antagonists as the agent of choice, whereas 20% used 		  sucralfate. These percentages are similar to the findings in another survey of 		  stress ulcer prophylaxis in which histamine-2-antagonists were used in 67% of 		  patients compared with 24% of patients receiving sucralfate. The majority of published studies using clinically 		  important bleeding as an end point have involved histamine-2-antagonists and 		  sucralfate. The most comprehensive meta-analysis  		  found no substantial differences in clinically important bleeding between the 		  latter agents, whereas the most recent and largest randomized trial suggested that ranitidine was more efficacious than 		  sucralfate (at least with the doses used in the trial). Trials involving other 		  agents such as the proton pump inhibitor omeprazole have either not used 		  clinically important bleeding as an end point or lacked sufficient power to 		  detect potential differences in bleeding between other agents or when compared 		  with placebo. Given the similar type of action (inhibition of acid release) 		  between histamine-2-antagonists and proton pump inhibitors, it seems likely 		  that the pump inhibitors would have similar efficacy.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>14939</offset><text>Given the inconsistent results of published investigations, it is 		  perhaps not surprising that almost all aspects of stress ulcer prophylaxis 		  remain controversial. Until some of the issues are resolved through further 		  study, there are a few recommendations that seem in order. First, it seems that 		  clinicians should aim for some form of consistency based on intra-institutional 		  guidelines using the most current, best evidence of prophylactic benefit with 		  histamine-2-receptor antagonists. A majority of institutions surveyed (73%) had 		  no guidelines in place. Of those that did have guidelines, almost half (48%) 		  had not been updated in the 2 years before receiving the survey. This finding 		  is of concern, because the most comprehensive meta-analysis and largest randomized study to 		  date concerning stress ulcer prophylaxis were published in the 2 years 		  preceding the survey. This finding could be misleading, however, because it is 		  possible that the results of these recent publications did not require an 		  alteration in the institution's guidelines.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16041</offset><text>Institutions contemplating the development of stress ulcer prophylaxis 		  guidelines should take advantage of existing information. One organization, the 		  American Society of Health-System Pharmacists, has recently promulgated 		  guidelines for stress ulcer prophylaxis that could be used as a template for 		  the intra-institutional development process. The 		  American Society of Health-System Pharmacists guidelines have an economic model 		  that can be modified using local efficacy, toxicity, and cost information.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16569</offset><text>There is another large survey that has been published concerning 		  stress ulcer prophylaxis. That survey, however, was 		  conducted in October 1995, which was before the publication of the largest 		  meta-analysis and largest randomized controlled trial to date. The present survey was conducted in the fall 		  of 1998, with one intention of determining how those reports may have 		  influenced prescribing habits. A second difference relates to the sample of 		  clinicians being surveyed. The previous study  		  selected a random sample of the members of the Society of Critical Care 		  Medicine who identified anesthesiology, surgery, or internal medicine as their 		  specialty area. The survey response rate was 26%. Our survey was sent to the 		  entire Section of Pharmacy and Pharmacology of the Society of Critical Care 		  Medicine, and had a response rate of 42%.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17452</offset><text>Another recommendation is to review stress ulcer prophylaxis 		  prescribing periodically, as well as any guidelines that are in place. Both 		  published literature and local evaluations may necessitate a change in the 		  guidelines. There are examples in the literature of where guideline changes 		  relative to stress ulcer prophylaxis have resulted in lowered institutional 		  costs without compromising the quality of patient care.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17892</offset><text>A final recommendation applies to those individuals who have the 		  capabilities of performing clinical studies concerning stress ulcer 		  prophylaxis. Although it seems unlikely that another study involving general 		  medical/surgical patients would resolve the debate concerning the need for 		  prophylaxis, randomized studies involving specialized populations (eg trauma 		  patients) could be of potential value, given the relative lack of controlled 		  investigations. Also, comparative studies involving newer medications and 		  different routes of administration are needed that use clinically important 		  bleeding as an end point.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18539</offset><text>Although the results of this survey describe some of the current 		  prescribing practices of physicians in the USA relative to stress ulcer 		  prophylaxis, there are important limitations to the information presented. Some 		  of the limitations concern questionnaires in general. For example, there are 		  concerns regarding the number and type of questions. If the instrument contains 		  an excessive number of questions, the responder may be less willing to complete 		  and return the material. This survey was limited to one page, front and back, 		  in an attempt to increase compliance. Another concern in common with all 		  questionnaires relates to the reliability and validity of the instrument, 		  although attempts were made to reduce such problems during the instrument 		  construction process.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19354</offset><text>Other limitations of these results pertain to the topic at hand (ie 		  stress ulcer prophylaxis). Physician prescribing and guideline development are 		  affected at different times and to varying degrees by published trials. The 		  largest randomized trial comparing ranitidine and sucralfate for stress ulcer 		  prophylaxis was published in March 1998. This survey 		  was mailed approximately 6 months after that publication. Therefore, physician 		  prescribing and institutional guidelines may not have changed as a result of 		  that trial at the time of the present survey. Additionally, the responses to 		  the survey questions are a function of the person completing the survey. 		  Because the individuals completing the survey were members of the Section of 		  Pharmacy and Pharmacology of the Society of Critical Care Medicine, it was 		  presumed that they were well versed in the area of stress ulcer prophylaxis 		  issues at their institutions.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20320</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20331</offset><text>There are wide variations in prescribing practices with regard to 		  stress ulcer prophylaxis, although such prophylaxis is used in the majority of 		  ICU patients. Histamine-2-antagonists, sucralfate, and proton pump inhibitors 		  are commonly used agents, with histamine-2-antagonists being the most commonly 		  preferred agent among the institutions surveyed. Published literature and 		  available guidelines should be used as a template for institutions that are 		  constructing their own guidelines.</text></passage><passage><infon key="fpage">308</infon><infon key="lpage">314</infon><infon key="name_0">surname:Cook;given-names:DJ</infon><infon key="name_1">surname:Reeve;given-names:BK</infon><infon key="name_2">surname:Guyatt;given-names:GH</infon><infon key="pub-id_pmid">8544272</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">275</infon><infon key="year">1996</infon><offset>20842</offset><text>Stress ulcer prophylaxis in critically ill patients.</text></passage><passage><infon key="fpage">791</infon><infon key="lpage">797</infon><infon key="name_0">surname:Cook;given-names:D</infon><infon key="name_1">surname:Guyatt;given-names:G</infon><infon key="name_2">surname:Marshall;given-names:J</infon><infon key="pub-id_pmid">9504939</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med </infon><infon key="type">ref</infon><infon key="volume">338</infon><infon key="year">1998</infon><offset>20895</offset><text>A comparison of sucralfate and ranitidine for the prevention of 			 upper gastrointestinal bleeding in patients requiring mechanical 			 ventilation.</text></passage><passage><infon key="fpage">189</infon><infon key="lpage">199</infon><infon key="name_0">surname:Schepp;given-names:W</infon><infon key="pub-id_pmid">7902305</infon><infon key="section_type">REF</infon><infon key="source">Digestion</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1993</infon><offset>21045</offset><text>Stress ulcer prophylaxis: still a valid option in the 			 1990's?</text></passage><passage><infon key="fpage">819</infon><infon key="lpage">826</infon><infon key="name_0">surname:Estruch;given-names:R</infon><infon key="name_1">surname:Pedrol;given-names:E</infon><infon key="name_2">surname:Castells;given-names:A</infon><infon key="pub-id_pmid">1771386</infon><infon key="section_type">REF</infon><infon key="source">Scand J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">1991</infon><offset>21111</offset><text>Prophylaxis of gastrointestinal tract bleeding with magaldrate in 			 patients admitted to a general hospital ward.</text></passage><passage><infon key="fpage">S19</infon><infon key="lpage">S25</infon><infon key="name_0">surname:Labattut;given-names:AG</infon><infon key="name_1">surname:Santolalla;given-names:PM</infon><infon key="name_2">surname:De Andres;given-names:AP</infon><infon key="section_type">REF</infon><infon key="source">Clin Intens Care</infon><infon key="type">ref</infon><infon key="volume">3 (suppl 5)</infon><infon key="year">1992</infon><offset>21227</offset><text>Efficacy of sucralfate in the prevention of upper gastrointestinal 			 stress bleeding in intensive care patients: comparison vs a control group. </text></passage><passage><infon key="fpage">645</infon><infon key="lpage">649</infon><infon key="name_0">surname:McAlhany;given-names:JC</infon><infon key="name_1">surname:Czaja;given-names:AJ</infon><infon key="name_2">surname:Pruitt;given-names:BA</infon><infon key="pub-id_pmid">785019</infon><infon key="section_type">REF</infon><infon key="source">J Trauma</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1976</infon><offset>21374</offset><text>Antacid control of complications from acute gastroduodenal disease 			 after burns.</text></passage><passage><infon key="fpage">1844</infon><infon key="lpage">1849</infon><infon key="name_0">surname:Metz;given-names:CA</infon><infon key="name_1">surname:Livingston;given-names:DH</infon><infon key="name_2">surname:Smith;given-names:JS</infon><infon key="name_3">surname:Larson;given-names:GM</infon><infon key="name_4">surname:Wilson;given-names:TH</infon><infon key="pub-id_pmid">8252888</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">1993</infon><offset>21458</offset><text>Impact of multiple risk factors and ranitidine prophylaxis on the 			 development of stress-related upper gastrointestinal bleeding: A prospective, 			 multicenter, double-blind, randomized trial.</text></passage><passage><infon key="fpage">413</infon><infon key="lpage">417</infon><infon key="name_0">surname:Chan;given-names:K</infon><infon key="name_1">surname:Lai;given-names:ECS</infon><infon key="name_2">surname:Tuen;given-names:H</infon><infon key="pub-id_pmid">7861219</infon><infon key="section_type">REF</infon><infon key="source">J Neurosurg</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1995</infon><offset>21655</offset><text>Prospective double-blind placebo-controlled randomized trial on the 			 use of ranitidine in preventing postoperative gastroduodenal complications in 			 high-risk neurosurgical patients.</text></passage><passage><infon key="fpage">377</infon><infon key="lpage">381</infon><infon key="name_0">surname:Cook;given-names:DJ</infon><infon key="name_1">surname:Fuller;given-names:HD</infon><infon key="name_2">surname:Guyatt;given-names:GH</infon><infon key="pub-id_pmid">8284001</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med </infon><infon key="type">ref</infon><infon key="volume">330</infon><infon key="year">1994</infon><offset>21843</offset><text>Risk factors for gastrointestinal bleeding in critically ill 			 patients.</text></passage><passage><infon key="fpage">98</infon><infon key="lpage">103</infon><infon key="name_0">surname:Lam;given-names:NP</infon><infon key="name_1">surname:Phuong-Dung;given-names:Tl</infon><infon key="name_2">surname:Crawford;given-names:SY</infon><infon key="name_3">surname:Patel;given-names:S</infon><infon key="pub-id_pmid">9934901</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">1999</infon><offset>21918</offset><text>National survey of stress ulcer prophylaxis.</text></passage><passage><infon key="fpage">347</infon><infon key="lpage">379</infon><infon key="pub-id_pmid">10690219</infon><infon key="section_type">REF</infon><infon key="source">Am J Health-Syst Pharm</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">1999</infon><offset>21963</offset><text>ASHP therapeutic guidelines on stress ulcer prophylaxis.</text></passage><passage><infon key="fpage">1678</infon><infon key="lpage">1684</infon><infon key="name_0">surname:Erstad;given-names:BL</infon><infon key="name_1">surname:Camamo;given-names:JM</infon><infon key="name_2">surname:Miller;given-names:MJ</infon><infon key="pub-id_pmid">9377882</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1997</infon><offset>22020</offset><text>Impacting cost and appropriateness of stress ulcer prophylaxis at a 			 university medical center.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>22119</offset><text>Figures and Tables</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>22138</offset><text>Stress ulcer prophylaxis in ICU and non-ICU settings</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;4&quot;&gt;Percentage of patients&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;4&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Percentage of institutions stating that:&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0⌓25&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26⌓50&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;51⌓75&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;76⌓100&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ICU patients received&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;76&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;stress ulcer prophylaxis&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Non-ICU patients received&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;34&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;44&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;stress ulcer prophylaxis&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Patients discharged from&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;35&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;the ICU to non-ICU settings&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;remained on stress ulcer prophylaxis&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>22191</offset><text>	Percentage of patients	 			 	Percentage of institutions stating that:	0⌓25	26⌓50	51⌓75	76⌓100	 	ICU patients received	0	7	17	76	 	stress ulcer prophylaxis					 	Non-ICU patients received	34	44	19	3	 	stress ulcer prophylaxis					 	Patients discharged from	35	32	23	10	 	the ICU to non-ICU settings					 	remained on stress ulcer prophylaxis					 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>22548</offset><text>ICU, intensive care unit.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>22574</offset><text>Specialized populations where stress ulcer prophylaxis is routinely administered</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Do not have&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Stress ulcer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Stress ulcer&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;substantial&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;prophylaxis&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;prophylaxis&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;numbers of&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Injury&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;is given&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;is not given&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;this injury&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Head injury&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;110&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Spinal cord injury&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;99&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Thermal injury&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;61&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;71&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Multiple trauma&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;106&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;34&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Hepatic injury with&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;67&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;62&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;need for partial resection&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>22655</offset><text>			Do not have	 		Stress ulcer	Stress ulcer	substantial	 		prophylaxis	prophylaxis	numbers of	 	Injury	is given	is not given	this injury	 	Head injury	110	3	30	 	Spinal cord injury	99	4	39	 	Thermal injury	61	3	71	 	Multiple trauma	106	3	34	 	Hepatic injury with	67	9	62	 	need for partial resection				 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>22961</offset><text>Data are expressed as number of institutions responding to the
question (not percentages).</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>23052</offset><text>Description of the route of administration for each institutions
			 preferred agent</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Agent&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Administration route&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Histamine-2-antagonist&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Intermittent IV&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;63&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;IV infusion&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Feeding tube&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;36&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Sucralfate&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Nasogastric tube&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Omeprazole&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Nasogastric tube&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;left&quot;&gt;Enteral tube&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Other&lt;/td&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>23137</offset><text>Agent	Administration route	n	 	Histamine-2-antagonist	Intermittent IV	63	 		IV infusion	13	 		Oral	27	 		Feeding tube	36	 	Sucralfate	Oral	13	 		Nasogastric tube	20	 	Omeprazole	Oral	4	 		Nasogastric tube	4	 		Enteral tube	2	 	Other		0	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>23376</offset><text>Responders were permitted to check more than one administration
route for their institution's preferred agent. IV, intravenous.</text></passage></document></collection>
